Perrigo Company plc (NYSE:PRGO) Receives $19.33 Average Price Target from Brokerages

Shares of Perrigo Company plc (NYSE:PRGO) have received a consensus rating of “Hold” from the six analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $19.3333.

A number of research analysts have commented on the company. Jefferies Financial Group reaffirmed a “hold” rating on shares of Perrigo in a report on Thursday, February 26th. Canaccord Genuity Group reduced their target price on Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Finally, Weiss Ratings raised Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday.

Perrigo Price Performance

Shares of NYSE PRGO opened at $10.66 on Wednesday. Perrigo has a fifty-two week low of $9.23 and a fifty-two week high of $28.43. The business has a 50 day moving average price of $11.18 and a two-hundred day moving average price of $12.41. The company has a quick ratio of 1.59, a current ratio of 2.72 and a debt-to-equity ratio of 1.45. The firm has a market cap of $1.47 billion, a PE ratio of -0.81, a price-to-earnings-growth ratio of 1.27 and a beta of 0.51.

Perrigo (NYSE:PRGO) last released its earnings results on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The company had revenue of $841.80 million for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter last year, the business posted $0.60 EPS. Perrigo’s quarterly revenue was down 7.2% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Sell-side analysts expect that Perrigo will post 2.11 earnings per share for the current fiscal year.

Perrigo Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Friday, May 29th were issued a dividend of $0.29 per share. This represents a $1.16 dividend on an annualized basis and a yield of 10.9%. The ex-dividend date of this dividend was Friday, May 29th. Perrigo’s dividend payout ratio (DPR) is currently -8.85%.

Institutional Trading of Perrigo

Several hedge funds have recently made changes to their positions in PRGO. Amundi lifted its holdings in shares of Perrigo by 11.7% in the 1st quarter. Amundi now owns 5,292 shares of the company’s stock worth $148,000 after purchasing an additional 556 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Perrigo by 126.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock worth $32,520,000 after purchasing an additional 647,982 shares during the last quarter. United Services Automobile Association bought a new stake in shares of Perrigo in the 1st quarter worth approximately $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Perrigo by 6.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,112 shares of the company’s stock worth $14,388,000 after purchasing an additional 32,151 shares during the last quarter. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after purchasing an additional 786 shares during the last quarter. Institutional investors own 95.91% of the company’s stock.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.